Efficacy and Safety Evaluation of CICAPLAST BAUME B5+ on Rosacea Accompanied by Sensitive Skin

Inclusion Criteria * 18-55 years old * Participants in the rosacea erythematous telangiectasia study or participants in the rosacea erythematous telangiectasia study who have not received treatment or have received treatment but are currently in a stable state (no treatment required). The treatment includes local medication, oral medication, phototherapy, or combined therapy * The score of the Persistent Erythema Assessment Scale (CEA) is between 1 and 3 points * The score of the Global Assessment Scale (IGA) is ≤2 points * Dry facial skin * People with sensitive skin (10% of those sensitive to lactic acid stinging) Exclusion Criteria * Intending to get pregnant, pregnant, lactating or within 6 months of delivery * Research participants with other facial skin diseases (such as seborrheic dermatitis, systemic lupus erythematosus, facial miliform lupus, contact dermatitis, hormone-dependent dermatitis, etc.) * Systemic diseases accompanied by severe organ damage, malignant tumors, chronic diseases with unstable control, acute infectious diseases, major surgeries or traumas, psychological and mental disorders, or other diseases that require local or systemic use of drugs or treatments that have an impact on acne * The test area is accompanied by other skin diseases (dermatitis, eczema, infection, tumor, etc.) or has other skin conditions that interfere with evaluation (birthmarks, scars, etc.) * Received physical, chemical or laser cosmetic surgery that is not for rosacea tre…